Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents

NCT01407978 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Novel 2009 Influenza H1N1
Influenza, Human

Interventions

BIOLOGICAL: Vaccination with Fluval P monovalent influenza vaccine
BIOLOGICAL: Vaccination with Fluval AB
BIOLOGICAL: Vaccination with Fluval AB Novo

Sponsor

Fluart Innovative Vaccine Ltd, Hungary